• FLEXcyte 96

  • FLEXcyte 96

  • FLEXcyte 96

  • FLEXcyte 96


Cardiomyocytes - "Chronic cardiotoxic effects of tyrosine kinase inhibitors and anthracyclines analyzed with the FLEXcyte 96 on human iPSC-derived cardiomyocytes"

Icon FLEX   FLEXcyte 96 application note  logo pdf   (0.4 MB)   kindly provided by InnoVitro GmbH


In cancer research, the intense development of targeted therapeutics such as tyrosine kinase inhibitors (TKIs) has brought tremendous improvement to the survival rate of cancer patients over the last two decades. The goal to reduce diverse toxic side effects of cancer treatment with targeted therapy has been widely achieved in comparison to traditional anti-cancer treatments like anthracyclines. Nevertheless, both therapeutics, TKIs and anthracyclines, still lead to adverse cardiotoxic side effects such as left ventricular dysfunction and heart failure.
The severity of these side effects depends on dosage and time span of treatment which brings chronic assessment of cardiotoxicity into focus.
However, acute testing (min to hours) of cell models with low predictive value remains the primary application so far, due to the inability of common cell-based assays to analyze cellular behavior reliably over prolonged periods of time.


FLEXcyte 96 Brochure

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.